STAGE IVB PROSTATE CANCER AJCC V8
Clinical trials for STAGE IVB PROSTATE CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IVB PROSTATE CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IVB PROSTATE CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare cancers: Triple-Drug attack shows promise
Disease control Recruiting nowThis phase II trial is testing whether a combination of three drugs—cabozantinib, nivolumab, and ipilimumab—can shrink or slow the growth of rare genitourinary cancers that have spread. About 314 adults with these uncommon tumors will receive the drugs. The goal is to see if the …
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 05:00 UTC
-
Engineered immune cells take on Hard-to-Treat prostate cancer
Disease control Recruiting nowThis study tests whether a new cell therapy called STEAP1 CAR T, given together with the hormone drug enzalutamide, is safe and effective for men with metastatic castration-resistant prostate cancer (mCRPC). The therapy uses a patient's own immune cells, modified in the lab to be…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Radioactive drug targets tough prostate cancer
Disease control Recruiting nowThis study tests a radioactive drug called lutetium Lu 177 dotatate in men with advanced prostate cancer that has neuroendocrine features. The drug seeks out and kills cancer cells that have a specific protein on their surface. The goal is to see if it can shrink tumors. About 35…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
PET scans guide new combo therapy to fight returning prostate cancer
Disease control Recruiting nowThis Phase III trial is testing whether using PET scans to guide treatment can help men whose prostate cancer has returned after surgery. For those without signs of spread outside the pelvis, researchers are adding a drug called apalutamide (plus other hormones) to standard radia…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a longer break between prostate cancer treatments boost quality of life?
Disease control Recruiting nowThis phase 3 trial for men with advanced, hormone-resistant prostate cancer tests whether giving the drug lutetium-177 PSMA less often (only when the disease shows signs of activity) can improve quality of life without shortening survival. About 1,500 participants will be randoml…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Testosterone therapy shows promise for Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-stage study tests a treatment called bipolar androgen therapy for men with advanced prostate cancer that no longer responds to standard hormone therapy. The treatment involves raising and lowering testosterone levels in a controlled way to try to slow cancer growth. Th…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug combo aims to halt tough prostate cancer
Disease control Recruiting nowThis study tests two drugs, cabozantinib and atezolizumab, in 33 men with a type of advanced prostate cancer that has spread and no longer responds to hormone therapy. The goal is to see if the combination can stop or shrink tumors. Participants must have non-measurable disease o…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: University of Utah • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Gene-Guided therapy could revolutionize prostate cancer care
Disease control Recruiting nowThis study tests whether analyzing a patient's tumor DNA and RNA can help doctors select the most effective treatment for advanced prostate cancer that no longer responds to hormone therapy. About 474 participants will receive one of several drugs based on their genetic profile. …
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Triple therapy may extend lives in advanced prostate cancer
Disease control Recruiting nowThis study tests whether adding the chemotherapy drug docetaxel to the usual hormone therapy and apalutamide helps men with prostate cancer that has spread to other parts of the body live longer. About 1,260 men will be randomly assigned to receive either the three-drug combinati…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for tough prostate cancer? drug combo enters early trial
Disease control Recruiting nowThis early-phase trial is testing whether adding ruxolitinib to the standard drug enzalutamide can help men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The study will enroll 20 participants to find the safest dose and check for early s…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New combo therapy aims to boost immune attack on Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-phase study tests whether adding an immune-boosting vaccine (Sipuleucel-T) to a radioactive drug (Lu-PSMA) is safe and works better than the radioactive drug alone for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. About 30…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
New trial aims to Fine-Tune prostate cancer treatment timing
Disease control Recruiting nowThis study looks at the best timing for combining targeted radiation (SBRT) with hormone therapy in men whose prostate cancer has returned and spread. It also tests if radiation to the pelvis can stop cancer from spreading further. About 532 men with recurrent, hormone-sensitive …
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
New combo aims to supercharge prostate cancer radiation
Disease control Recruiting nowThis study tests whether giving abemaciclib before a radioactive drug (177Lu-PSMA-617) can make prostate cancer cells more sensitive to radiation. About 30 men with advanced, treatment-resistant prostate cancer will receive abemaciclib pills for two weeks, then the radioactive th…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: Vadim S Koshkin • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New hope for advanced prostate cancer: PET-Guided radiation may delay progression
Disease control Recruiting nowThis study tests whether adding targeted radiation, guided by a special PET scan, to standard hormone therapy can better control prostate cancer that has spread. About 125 men with metastatic hormone-sensitive prostate cancer will be randomly assigned to receive either standard t…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New targeted radiation therapy shows promise for Tough-to-Treat prostate cancer
Disease control Recruiting nowThis study tests a drug called 177Lu-PSMA-617, which delivers radiation directly to prostate cancer cells to damage their DNA. It is for people with prostate cancer that has spread and is no longer responding to hormone therapy. The goal is to see if this treatment can slow cance…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Second dose of targeted radiation shows promise for tough prostate cancer
Disease control Recruiting nowThis study tests whether giving a second round of a radioactive drug called 177Lu-PSMA-617 can help men with advanced prostate cancer that no longer responds to hormone therapy. The drug targets and delivers radiation directly to cancer cells. Participants must have already had a…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New combo aims to make resistant prostate cancer vulnerable to radiation
Disease control Recruiting nowThis phase 2 trial tests whether adding vorinostat to the radioactive drug 177Lu-PSMA-617 can help men with PSMA-low metastatic castration-resistant prostate cancer. The goal is to increase PSMA levels on cancer cells so the radiation therapy works better. About 15 participants w…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New combo targets advanced prostate cancer in phase 2 trial
Disease control Recruiting nowThis study tests whether adding the drug talazoparib to standard hormone therapy can better control advanced prostate cancer that still responds to hormone treatment. About 70 men with cancer that has spread will receive the combination. The goal is to see if this approach lowers…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Double chemo attack may stall tough prostate cancer
Disease control Recruiting nowThis phase III trial tests whether adding carboplatin to the standard chemo drug cabazitaxel helps men with metastatic castrate-resistant prostate cancer live longer without their cancer worsening. About 528 men will be randomly assigned to get cabazitaxel alone or cabazitaxel pl…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Could High-Dose testosterone boost chemo against Hard-to-Treat prostate cancer?
Disease control Recruiting nowThis phase 2 trial tests whether giving high levels of testosterone alongside chemotherapy (carboplatin or etoposide) or a targeted radioactive drug (LuPSMA) can shrink tumors in men with advanced prostate cancer that has stopped responding to hormone therapy. The study will enro…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Engineered immune cells take on Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-phase trial is testing a new treatment for men with a tough-to-treat form of prostate cancer that has spread and no longer responds to hormone therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells t…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Could fewer doses of this prostate cancer drug be just as good?
Disease control Recruiting nowThis phase II trial is testing whether giving 5 cycles of the radioactive drug Lu-177 PSMA-617 works as well as the standard 6 cycles for men with metastatic castration-resistant prostate cancer. The goal is to see if a shorter treatment course can control the cancer just as effe…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 26, 2026 15:59 UTC
-
Can treating the original tumor boost survival in advanced prostate cancer?
Disease control Recruiting nowThis phase 3 trial is testing whether adding surgery to remove the prostate or radiation therapy to standard drug treatment helps people with prostate cancer that has spread to other parts of the body. About 1,273 participants will receive either standard therapy alone or standar…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 26, 2026 15:45 UTC
-
Freezing and zapping: new combo therapy aims to ease bone cancer pain
Symptom relief Recruiting nowThis study tests whether adding cryoablation (a procedure that freezes and kills cancer cells) to standard radiation therapy provides better pain relief for people whose cancer has spread to their bones. About 40 participants with various cancers will be split into two groups: on…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:07 UTC
-
Biopsies reveal secrets of therapy resistance in advanced prostate cancer
Knowledge-focused Recruiting nowThis study looks at why some prostate cancers become resistant to a targeted radiation treatment called 177Lu-PSMA. Researchers will take small tissue samples (biopsies) from tumors in 30 patients before and after therapy. The goal is to find genetic changes that cause resistance…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Can DNA glitches predict prostate cancer treatment success?
Knowledge-focused Recruiting nowThis study looks at men with advanced prostate cancer that has spread to the bones. Researchers want to see if certain DNA repair problems in the cancer cells make the drug radium-223 work better or worse. The goal is to help doctors choose the best treatment for each patient in …
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Sponsor: University of Washington • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
Tailored care plans aim to bridge health literacy gap for black prostate cancer survivors
Knowledge-focused Recruiting nowThis study compares a standard survivorship care plan to one tailored for low health literacy in 150 African American men who have finished treatment for localized or limited-spread prostate cancer. The goal is to see if the tailored plan helps them better understand their follow…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: NA • Sponsor: Emory University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC